Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aramchol in NASH (ARMOR)
NCT04104321Phase 3Suspended
- Sponsor
- Galmed Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aramchol in Nonalcoholic steatohepatitis (NASH), sponsored by Galmed Pharmaceuticals. Primary endpoints: Improvement of Fibrosis Based on Liver Biopsy at 120 weeks, NASH Resolution at 72 weeks and 4 more. Started Sep 2019; status: suspended.
02
Drugs
aramchol
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04104321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04104321.